Announced Thu, 25 Jun · 10:03 IST
Concord Biotech clears Kenya, Uganda drug inspections at Unit-II facility
CONCORDBIO · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Price reaction · full curve 14 horizons · vs prior close
-1.6%1-day move
₹1289.90
prior close
₹1298.50
base price
In-mkt
timing
5m10m15m30m1D2D3D4D5D7D15D1M2M3M
+0.1+0.0-0.1+0.1-1.6-0.5-0.2-0.4-0.6-1.5+3.8-1.9——
Up moveDown movePending
AI summary
Concord Biotech successfully completed inspections by Kenya's Pharmacy and Poisons Board (PPB) and Uganda's National Drug Authority (NDA) at its Unit-II formulation facility between June 18 and June 24, 2026. The clearance enables the company to supply pharmaceutical products in Kenya and Uganda and strengthens its global manufacturing and regulatory footprint in African markets.
Likely market impact
Opens African markets for Concord Biotech's formulations, supporting international revenue growth and validating quality standards for future regulatory approvals.